Clinical trials: Substance Use Disorders, open to volunteers
- Condition Substance Use Disorders
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Opioid Withdrawal, Opioid Use Disorder
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
The primary objective of this trial is to measure changes in physiologic signals to quantify the status of the autonomic nervous system during opioid withdrawal and cravings.
- Trial name
- NCT06487533
- Testing
- EmbracePlus Smartwatch, Corti Sensor
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Alcohol Use Disorder
A Study of Brenipatide in Participants With Alcohol Use Disorder
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use.
- Trial name
- RENEW-ALC-2 (NCT07219953)
- Testing
- LY3537031
- Where
- 115 sites in United States, Belgium and 6 more
- Volunteers
- 1,100 people
- Sponsor
- Eli Lilly and Company
Opioid Use Disorder
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support…
- Trial name
- NCT07169409
- Testing
- Telemedicine Buprenorphine Treatment
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Boulder Care
Relationship Conflict, Relationship Distress
OurRelationship-S: A Digital Relationship-Strengthening Program for Couples Experiencing Substance Misuse
This study tests the effectiveness of an online relationship program that has been tailored for couples in which one or both members are in recovery from substance misuse.
- Trial name
- NCT07159633
- Testing
- Online Couple Intervention
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- OurRelationship
Alcohol Use Disorder
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
The primary objective of this study is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in Healthy Volunteers (HV) and Subjects with…
- Trial name
- NCT05913752
- Testing
- CMND-100
- Where
- 4 sites in United States, Israel
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Clearmind Medicine Inc.
Opioid Withdrawal (Disorder), Opioid Use Disorder
Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms
This study aims to evaluate the safety and efficacy of a physical device for medical use (ADTPM 1) applied to opioid withdrawal symptoms.
- Trial name
- NCT07079215
- Testing
- Neurostimulation
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Nu Eyne Co., Ltd.
Opioid Use Disorder
AvertD Post-Approval Study
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
- Trial name
- NCT07135323
- Testing
- Opioid Used Disorder Risk Assessment
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Prescient Medicine Holdings, Inc.
Opioid Use Disorder
A Study of Brenipatide in Participants With Opioid Use Disorder
The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone.
- Trial name
- RENEW-Op-1 (NCT07420283)
- Testing
- Brenipatide, Buprenorphine
- Where
- 68 sites in United States, Canada and 2 more
- Volunteers
- 465 people
- Sponsor
- Eli Lilly and Company
Substance Use Disorders, Alcohol Use Disorders
DEVELOPMENT OF A NOVEL PEER RECOVERY SUPPORTER TRAINING PLATFORM
This study tests an online training platform for peer recovery support specialists, people in recovery who support others with alcohol and other substance use problems.
- Conditions
- Substance Use Disorders, Alcohol Use Disorders, Recovery Support Services, Peer Recovery Coaching
- Trial name
- NCT07044531
- Testing
- Training-as-Usual (TAU), TDPP-A (Asynchronous Platform), TDPP-Z (Hybrid)
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Thrive Digital Health, LLC
Opioid Use Disorder
PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study
The goal of this clinical trial is to learn if it is feasible to use PEX010 for the treatment of opioid use disorder in adults. The study will also assess the safety of PEX010.
- Trial name
- NCT06608459
- Testing
- PEX010-Assisted Therapy
- Volunteers
- 10 people
- Sponsor
- Filament Health Corp.
Alcohol Use Disorder, Alcoholism
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)
The study will compare alcohol use in two groups of subjects. One group will be assigned to the Deep TMS treatment and the other group will be assigned to the sham treatment.
- Conditions
- Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Alcohol Dependence
- Trial name
- NCT07216872
- Testing
- Deep TMS (DTMS)
- Where
- 11 sites in United States, Israel and 1 more
- Volunteers
- 186 people
- Sponsor
- Brainsway
Chronic Pain, Pain
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids.
- Conditions
- Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
- Trial name
- NCT07874620
- Testing
- Cebranopadol
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Adneuris Therapeutics, Inc.
Alcohol Use Disorder
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
- Trial name
- RENEW-ALC-1 (NCT07219966)
- Testing
- LY3537031
- Where
- 117 sites in United States, Belgium and 6 more
- Volunteers
- 1,100 people
- Sponsor
- Eli Lilly and Company
Anxiety, Depressive Symptoms
Efficacy of Digital Problem Solving Application in Reduction of Anxiety, Depression and Substance Use Disorder Symptoms
The focus of this study is the impact of usage of a mobile application to support problem-solving therapy on symptoms of anxiety, depression and substance use.
- Conditions
- Anxiety, Depressive Symptoms, Substance Use Disorders
- Trial name
- Efficacy (NCT06346431)
- Testing
- DSPT - Digital Support for Problem-solving Therapy
- Volunteers
- 100 people
- Sponsor
- 7 Generation Games
Alcohol Abuse, Alcohol Abuse/addiction
A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.
- Conditions
- Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold
- Trial name
- NCT06710431
- Testing
- AFA-281
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Afasci Inc
Substance Use Disorder (SUD)
Study to Confirm the AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder (ATTESTED)
The purpose of this phase III, randomized, double-blind, placebo-controlled study is to confirm the authenticity of point-of-care urine samples in adult persons with substance use disorder using fluorescein sodium as a marker.
- Trial name
- ATTESTED (NCT07356349)
- Testing
- Fluorescein
- Volunteers
- 114 people
- Sponsor
- UpTru Inc.
Opioid Use Disorder
Remotely Observed Methadone Evaluation II
Methadone is an effective treatment for severe opioid use disorder (OUD), but access is limited due to the requirement of daily observed dosing by most opioid treatment programs (OTPs).
- Trial name
- ROME II (NCT06338280)
- Testing
- Sonara
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sonara Health
Substance Use Disorders (SUDs)
Cogito: A Turnkey Solution for Rapidly Developing, Evaluating, Deploying, and Scaling Digital Therapeutics
This is a research study to evaluate the usability of the Cogito digital therapeutics development platform. The Cogito platform is designed to allow researchers who are seeking to embed an evidence-based behavioral therapy into a…
- Trial name
- NCT07104396
- Testing
- Cogito digital therapeutics development platform
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Square2 Systems, Inc.
Alcohol, Alcohol Use Disorders
A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers
The goal of this clinical trial is to evaluate if alcohol interacts with the drug candidate AFA-281 in adults (healthy volunteers). This trial will evaluate blood concentration levels of AFA-281 and ethanol.
- Trial name
- NCT06719908
- Testing
- AFA-281 is a small molecule, orally available, Alcohol (Ethanol)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Afasci Inc
Substance Use, Substance Abuse
Mobile Technology to Reduce Teen Substance Misuse
The goal of this study is to test the newly expanded WisePath for Teens (WPT) for substance use app, a direct-to-consumer paired mobile phone app for iOS and Android platforms that supports parents/guardians in delivering…
- Conditions
- Substance Use, Substance Abuse, Suicide, Adolescent
- Trial name
- NCT05897164
- Testing
- WisePath for Teens, Peer Support Services (PSS), Control
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA